Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and the US for use in patients with type 2 diabetes. This review summarizes current evidence from clinical trials assessing the clinical efficacy and safety of dapagliflozin, and presents data regarding its cost-effectiveness. Treatment with dapagliflozin results in similar reduction in haemoglobin A1c with other oral antihyperglycaemic drugs, which is preserved over 4 years of treatment. However, compared with most antidiabetic agents, dapagliflozin provides additional clinical benefits including body weight loss and blood pressure reduction. Moreover, treatment with dapagliflozin does not increase risk for hypoglycaemia, but is associated with increased incidence of mild to moderate urinary and genital tract infections. A pivotal outcomes trial of dapagliflozin is expected to clarify its effect on cardiovascular endpoints, whilst a causative relationship between dapagliflozin and select malignancies is unlikely. Finally, based on recent economic evaluations dapagliflozin seems to be a cost-effective option for type 2 diabetes in some settings.

Keywords: BMS512148; Farxiga®; Forxiga®; Xigduo®; cost-effectiveness; dapagliflozin; sodium–glucose cotransporter 2 (SGLT2); type 2 diabetes mellitus.

Conflict of interest statement

Conflict of interest statement: A.T. has received lecture fees from AstraZeneca and Boehringer Ingelheim, and research support from Boehringer Ingelheim, Novartis, Novo Nordisk and Sanofi. The remaining authors declare no conflicts of interest in preparing this article.